This set of compounds is characterized by a 3 to 12-membered heterocyclic ring containing at least two heteroatoms which interact with the carboxyl groups of the aspartic acid residues of the HIV protease. Such chemical structure and low molecular weight make them more water soluble than other currently available drugs.
Combinatorial methods can be applicable for optimizing the structure.
For these reasons, this invention may be of interest to the pharmaceutical industry as a potential treatment of diseases through protease inhibition. The heterocyclic aspartic protease inhibitors has the potential to be an important template for the development of inhibitors targeting beta-secretase. The Kansas State University Research Foundation is seeking organizations interested in licensing, developing and commercializing the technology. For additional information please contact the Mid-America Commercialization Corporation.